Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu, Rengyun Liu, Xiaopei Shen, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 2, pp. 177-182
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Current practice in patients with differentiated thyroid cancer
Martin Schlumberger, Sophie Leboulleux
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 3, pp. 176-188
Closed Access | Times Cited: 253
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
Furio Pacini, Dagmar Führer, Rossella Elisei, et al.
European Thyroid Journal (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 79
Genomic alterations in thyroid cancer: biological and clinical insights
Iñigo Landa, Maria E. Cabanillas
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 2, pp. 93-110
Closed Access | Times Cited: 43
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS
Ji Min Oh, Byeong‐Cheol Ahn
Theranostics (2021) Vol. 11, Iss. 13, pp. 6251-6277
Open Access | Times Cited: 90
Pathogenesis of cancers derived from thyroid follicular cells
James A. Fagin, Gnana P. Krishnamoorthy, Iñigo Landa
Nature reviews. Cancer (2023) Vol. 23, Iss. 9, pp. 631-650
Open Access | Times Cited: 29
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
Sarah Hamidi, Marie‐Claude Hofmann, Priyanka Iyer, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 23
Integrated Diagnostics of Thyroid Nodules
Luca Giovanella, Alfredo Campennì, Murat Tuncel, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 311-311
Open Access | Times Cited: 11
Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer
Zhuanzhuan Mu, Xin Zhang, Dongquan Liang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 1, pp. 25-35
Open Access | Times Cited: 9
Bone Mineral Density: Clinical Relevance and Quantitative Assessment
Katherine Haseltine, Tariq Chukir, Pinar J. Smith, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 4, pp. 446-454
Open Access | Times Cited: 62
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy
Amandeep Singh, Jeehoon Ham, Joseph W. Po, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1082-1082
Open Access | Times Cited: 51
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Louise Schubert, A. M. Mbekwe-Yepnang, Johanna Wassermann, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 6, pp. 1573-1581
Open Access | Times Cited: 7
Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Fabio Volpe, Carmela Nappi, Emilia Zampella, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3870-3884
Open Access | Times Cited: 7
The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis
Bojie Chen, Yuan Shi, Yanan Xu, et al.
Clinical Endocrinology (2020) Vol. 94, Iss. 5, pp. 731-742
Open Access | Times Cited: 42
Redifferentiation-facilitated radioiodine therapy in thyroid cancer
Livia Lamartina, Nadège Anizan, Corinne Dupuy, et al.
Endocrine Related Cancer (2021) Vol. 28, Iss. 10, pp. T179-T191
Open Access | Times Cited: 39
The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer
Jingjia Cao, Xiaolu Zhu, Yaru Sun, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 10, pp. 3470-3481
Closed Access | Times Cited: 25
The lymph node yield in the initial lateral neck dissection predicts recurrence in the lateral neck of papillary thyroid carcinoma: a revision surgery cohort study
Shitong Yu, Jun-Na Ge, Zhigang Wei, et al.
International Journal of Surgery (2023) Vol. 109, Iss. 5, pp. 1264-1270
Open Access | Times Cited: 15
<i>TERT</i> promoter mutations in thyroid cancer
Michiko Matsuse, Norisato Mitsutake
Endocrine Journal (2023) Vol. 70, Iss. 11, pp. 1035-1049
Open Access | Times Cited: 14
<i>BRAF</i> and <i>TERT</i> promoter mutations: clinical application in thyroid cancer
Jae Hoon Chung
Endocrine Journal (2020) Vol. 67, Iss. 6, pp. 577-584
Open Access | Times Cited: 39
Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Yi Luo, Hongyi Jiang, Weibo Xu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 36
Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
Paula Soares, Antónia Póvoa, Miguel Melo, et al.
Endocrine Pathology (2021) Vol. 32, Iss. 1, pp. 44-62
Closed Access | Times Cited: 28
Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score
Laura Boucai, Venkatraman Seshan, Michelle D. Williams, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. 1030-1039
Open Access | Times Cited: 28
Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
Jingxin Mao, Xingliang Huang, Mohammad K. Okla, et al.
Computational and Mathematical Methods in Medicine (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 19
A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
Chao Meng, Juanjuan Song, Long Wen, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 12
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
Huize Shen, Rui Zhu, Yanyang Liu, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101013-101013
Open Access | Times Cited: 12
Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer
Ye Sang, Guanghui Hu, Junyu Xue, et al.
Endocrine (2024) Vol. 85, Iss. 1, pp. 304-312
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top